Profile data is unavailable for this security.
About the company
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
- Revenue in USD (TTM)0.00
- Net income in USD-32.66m
- Incorporated2005
- Employees92.00
- LocationXBiotech Inc5217 WINNEBAGO LANEAUSTIN 78744United StatesUSA
- Phone+1 (512) 386-2900
- Websitehttp://www.xbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zura Bio Ltd | 0.00 | -42.62m | 191.31m | 14.00 | -- | 1.25 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 195.64m | 265.00 | -- | 1.11 | -- | 3.17 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 197.27m | 145.00 | -- | 1.32 | -- | 2.74 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Acrivon Therapeutics Inc | 0.00 | -76.98m | 199.46m | 58.00 | -- | 1.02 | -- | -- | -2.70 | -2.70 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -42.09 | -- | -45.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -69.12m | 201.18m | 9.00 | -- | 0.9218 | -- | -- | -2.13 | -2.13 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -41.28 | -- | -42.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 201.47m | 339.00 | -- | 1.68 | -- | 1.43 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XBiotech Inc | 0.00 | -32.66m | 201.67m | 92.00 | -- | 1.05 | -- | -- | -1.07 | -1.07 | 0.00 | 6.30 | 0.00 | -- | -- | 0.00 | -14.86 | 31.88 | -15.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0495 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Perspective Therapeutics Inc | -3.68m | -53.78m | 202.28m | 116.00 | -- | 0.6171 | -- | -- | -1.24 | -1.59 | -0.069 | 4.86 | -0.0147 | -- | -- | -31,741.38 | -21.44 | -- | -23.11 | -- | -- | -- | -- | -- | -- | -- | 0.0051 | -- | -- | -- | -- | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -38.70m | 203.76m | 19.00 | -- | 1.35 | -- | -- | -4.69 | -4.69 | 0.00 | 12.36 | 0.00 | -- | -- | 0.00 | -38.61 | -86.84 | -49.21 | -130.46 | -- | -- | -- | -769.76 | -- | -- | 0.00 | -- | -- | -- | -5.33 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -86.60m | 204.98m | 58.00 | -- | 1.47 | -- | -- | -2.89 | -2.89 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -75.77 | -- | -96.90 | -- | -- | -- | -- | -- | -- | -- | 0.0107 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Sutro Biopharma Inc | 160.96m | -123.95m | 207.37m | 306.00 | -- | 1.87 | -- | 1.29 | -1.62 | -1.62 | 2.25 | 1.35 | 0.3643 | -- | 13.83 | 532,963.60 | -28.06 | -25.48 | -36.53 | -29.75 | -- | -- | -77.01 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Tscan Therapeutics Inc | 9.36m | -111.30m | 208.72m | 188.00 | -- | 0.9176 | -- | 22.29 | -1.05 | -1.05 | 0.0887 | 4.29 | 0.0293 | -- | -- | 60,792.21 | -34.81 | -- | -38.54 | -- | -- | -- | -1,188.88 | -- | -- | -- | 0.118 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 208.96m | 88.00 | -- | 1.22 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 209.84m | 25.00 | -- | 3.49 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Onkure Therapeutics Inc | 0.00 | -41.03m | 213.30m | 8.00 | -- | 0.7223 | -- | -- | -12.25 | -12.25 | 0.00 | 22.14 | 0.00 | -- | -- | 0.00 | -39.45 | -- | -42.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to XBiotech Inc's reporting currency: US Dollar USD
13.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.13m | 3.70% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.05m | 3.43% |
| Geode Capital Management LLCas of 30 Sep 2024 | 452.26k | 1.49% |
| Millennium Management LLCas of 30 Sep 2024 | 281.02k | 0.92% |
| MultiConcept Fund Management SAas of 30 Sep 2024 | 253.77k | 0.83% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 224.60k | 0.74% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 173.42k | 0.57% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 147.59k | 0.48% |
| American Century Investment Management, Inc.as of 30 Sep 2024 | 130.18k | 0.43% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 128.35k | 0.42% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
